BGOG-ov-50
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)
Sponsor: Novocure
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Gent, Gent
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- AZ Maria Middelares, Gent
- CHU Dinant Godinne, Yvoir
- Grand Hôpital de Charleroi, Charleroi
- Imelda ziekenhuis, Bonheiden
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-46
Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
Sponsor: AstraZeneca
Participating sites:
- AZ Nikolaas, St-Niklaas
- AZ Damiaan, Oostende
- OLV Aalst, Aalst
- UZ Leuven, Leuven
- CHU UCL Namur, site Sainte Elisabeth, Namur
Learn More ->
BGOG-ov-44
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- AZ Sint-Jan Brugge, Brugge
- CHU St. Pierre, Bruxelles
- AZ Klina, Brasschaat
Learn More ->
BGOG-ov-43
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Maria Middelares, Gent
- Imelda Ziekenhuis, Bonheiden
- Grand Hôpital de Charleroi, Charleroi
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- UZ Gent, Gent
- Jessa Ziekenhuis, Hasselt
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-41
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Participating sites:
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- CHU UCL Namur, site Sainte Elisabeth, Namur
- CHU UCL St. Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU de Liège, site Sart Tilman, Liège
Learn More ->
BGOG-ov-55
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Sponsor: ImmunoGen
Participating sites:
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- OLV Aalst, Aalst
- UZ Antwerpen, Antwerpen
- AZ Sint Lucas, Gent
- AZ Klina, Roeselare
Learn More ->